vestibИзвестия Национальной академии наук Беларуси. Серия биологических наукProceedings of the National Academy of Sciences of Belarus, Biological Series1029-89402524-230XThe Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1029-8940-2022-67-4-419-425vestib-840Research ArticleОБЗОРЫREVIEWSТоксичность полиамидоаминных дендримеров in vivoToxicity of polyamidoamine dendrimers in vivoСтановаяА. И.StanavayaA. I.

Становая Алеся Игоревна – науч. сотрудник

ул. Академическая, 27, 220072, г. Минск

Alesia I. Stanavaya – Researcher

27, Akademicheskaya Str., 220072, Minsk

alesiastanovaya@gmail.comАбашкинВ. М.AbashkinV. M.

Абашкин Виктор Михайлович – науч. сотрудник

ул. Академическая, 27, 220072, г. Минск

Viktar M. Abashkin – Researcher

27, Akademicheskaya Str., 220072, Minsk

viktar.abashkin@gmail.comВчерашняяА. В.VcherashniayaA. V.

Вчерашняя Александра Васильевна – канд. биол. наук, ст. науч. сотрудник

ул. Академическая, 27, 220072, г. Минск

Aliaksandra V. Vcherashniaya – Ph. D. (Biol.), Senior Researcher

27, Akademicheskaya Str., 220072, Minsk

vcherashniaya@gmail.comТереховаМ. М.TerehovaM. M.

Терехова Мария Михайловна – мл. науч. сотрудник

ул. Академическая, 27, 220072, г. Минск

Maria M. Terehova – Junior Researcher

27, Akademicheskaya Str., 220072, Minsk

maryterekhova@tut.byЖоглаВ. А.ZhoglaV. A.

Жогла Виктория Андреевна – мл. науч. сотрудник

ул. Академическая, 27, 220072, г. Минск

Victoriya A. Zhogla – Junior Researcher

27, Akademicheskaya Str., 220072, Minsk

victoriya.zhogla@gmail.comГалец-БуйИ. В.Halets-BuiI. V.

Галец-Буй Инесса Веславовна – канд. биол. наук, ст. науч. сотрудник

ул. Академическая, 27, 220072, г. Минск

Inessa V. Halets-Bui – Ph. D. (Biol.), Senior Researcher

27, Akademicheskaya Str., 220072, Minsk

inessahalets@gmail.comЖивицкаяС. С.ZhyvitskayaS. S.

Живицкая Славяна Сергеевна – студент

пр. Независимости, 4, 220030, г. Минск

Slaviana S. Zhyvitskaya – Studen

4, Nezavisimosti Ave., 220030, Minsk

slaviankazhivicka@gmail.comЩербинД. Г.ShcharbinD. G.

Щербин Дмитрий Григорьевич – д-р биол. наук, доцент, заведующий лабораторией

ул. Академическая, 27, 220072, г. Минск

Dzmitry G. Shcharbin – D. Sc. (Biol.), Associate Professor, Head of the Laboratory

27, Akademicheskaya Str., 220072, Minsk

 

shcharbin@gmail.comИнститут биофизики и клеточной инженерии НАН БеларусиInstitute of Biophysics and Cell Engineering of the National Academy of Sciences of BelarusБелорусский государственный университетBelarusian State University202202112022674419425Copyright © Становая А.И., Абашкин В.М., Вчерашняя А.В., Терехова М.М., Жогла В.А., Галец-Буй И.В., Живицкая С.С., Щербин Д.Г., 20222022Становая А.И., Абашкин В.М., Вчерашняя А.В., Терехова М.М., Жогла В.А., Галец-Буй И.В., Живицкая С.С., Щербин Д.Г.Stanavaya A.I., Abashkin V.M., Vcherashniaya A.V., Terehova M.M., Zhogla V.A., Halets-Bui I.V., Zhyvitskaya S.S., Shcharbin D.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestibio.belnauka.by/jour/article/view/840

Одной из важных задач современной медицины является создание эффективных средств доставки лекарственных препаратов различной природы. При разработке таких систем в первую очередь возникает проблема токсичности для организма человека используемых соединений и структур.

В данном обзоре проанализирована литература, в которой охарактеризована токсичность полиамидоаминных (ПАМАМ) дендримеров in vivo. Результаты исследований показывают, что токсичность ПАМАМ дендримеров зависит от их физических параметров (размерa, генерации, поверхностного зарядa), используемой дозы и способа введения. Показано, что катионные ПАМАМ дендримеры малых и средних генераций нетоксичны in vivo при внутривенном и внутрибрюшинном введении мышам в дозах до 10 мг/кг. В свою очередь анионные, нейтральные и модифицированные ПАМАМ дендримеры не проявляют токсичности независимо от способа введения. Таким образом, варьируя способы введения, величину дозы, осуществляя модификации поверхности дендримеров, можно достичь снижения токсичности и с успехом применять их в качестве носителей лекарственных препаратов.

The development of effective drug delivery systems is a crusial task for modern medicine. The main problem is the occurrence of non-specific toxicity leading to undesirable side effects in vivo.

This article aims at reviewing resent research on the toxicity of polyamidoamine (PAMAM) dendrimers in vivo. The research results show that the toxicity of PAMAM dendrimers and modified nanoparticles depends both on the characteristics of the particles themselves (size, generation and surface charge) and on the administration parameters. It has been shown that cationic PAMAM dendrimers of small and medium generations are non-toxic in vivo when administered intravenously and intraperitoneally to mice at doses up to 10 mg/kg. In turn, anionic, neutral, and modified PAMAM dendrimers do not exhibit toxicity, regardless of the route of administration. Thus, by varying methods of administration, the dose, and modifying the surface of dendrimers, the decrease in toxicity can be achieved, promising a path towards their successfully aplication as drug carriers.

наноматериалыПАМАМ дендримерыповерхностный зарядтоксичность in vivoмышикрысыnanomaterialsPAMAM dendrimerssurface chargein vivo toxicitymiceratsReferencesA new class of polymers: Starburst-dendritic macromolecules / D. A. Tomalia [et al.] // Polym. J. – 1985. – Vol. 17, N 1. – P. 117–132. https://doi.org/10.1295/polymj.17.117Tomalia D. A., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Ryder J., Smith P. A new class of polymers: Starburst-dendritic macromolecules. Polymer Journal, 1985, vol. 17, no. 1, pp. 117–132. https://doi.org/10.1295/ polymj.17.117Roberts, J. C. Preliminary biological evaluation of polyamidoamine (PAMAM) StarburstTM dendrimers / J. C. Roberts, M. K. Bhalgat, R. T. Zera // J. Biomed. Mater. Res. – 1996. – Vol. 30, N 1. – P. 53–65. https://doi.org/10.1002/(SICI)1097- 4636(199601)30:13.0.CO;2-QRoberts J. C., Bhalgat M. K., Zera R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) StarburstTM dendrimers. Journal of Biomedical Materials Research, 1996, vol. 30, no. 1, pp. 53–65. https://doi.org/10.1002/(SICI)1097- 4636(199601)30:13.0.CO;2-QHepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex / M. Mamede [et al.] // J. Control. Release. – 2004. – Vol. 95, N 1. – P. 133–141. https://doi.org/10.1016/j.jconrel.2003.11.015Mamede M., Saga T., Ishimori T., Higashi T., Sato N., Kobayashi H., Brechbiel M. W., Konishi J. Hepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex. Journal of Controlled Release, 2004, vol. 95, no. 1, pp. 133–141. https://doi.org/10.1016/j.jconrel.2003.11.015Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo / N. Malik [et al.] // J. Control. Release. – 2000. – Vol. 65, N 1–2. – P. 133–148. https://doi.org/10.1016/S0168-3659(99)00246-1Malik N., Wiwattanapatapee R., Klopsch R., Lorenz K., Frey H., Weener J. W., Meijer E. W., Paulus W., Duncan R. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. Journal of Controlled Release, 2000, vol. 65, no. 1–2, pp. 133–148. https://doi.org/10.1016/S0168-3659(99)00246-1Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration / T. Okuda [et al.] // J. Control. Release. – 2006. – Vol. 114, N 1. – P. 69–77. https://doi.org/10.1016/j.jconrel.2006.05.009Okuda T., Kawakami S., Maeie T., Niidome T., Yamashita F., Hashida M. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. Journal of Controlled Release, 2006, vol. 114, no. 1, pp. 69–77. https://doi.org/10.1016/j.jconrel.2006.05.009Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired bloodbrain barrier permeability in streptozotocin diabetes in rats / K. Karolczak [et al.] // Int. J. Pharm. – 2012. – Vol. 436, N 1–2. – P. 508–518. https://doi.org/10.1016/j.ijpharm.2012.06.033Karolczak K., Rozalska S., Wieczorek M., Labieniec-Watala M., Watala C. Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired blood-brain barrier permeability in streptozotocin diabetes in rats. International Journal of Pharmaceutics, 2012, vol. 436, no. 1–2, pp. 508–518. https://doi.org/10.1016/j. ijpharm.2012.06.033Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers / A. S. Chauhan [et al.] // Biomacromolecules. – 2009. – Vol. 10, N 5. – P. 1195–1202. https://doi.org/10.1021/ bm9000298Chauhan A. S., Diwan P. V., Jain N. K., Tomalia D. A. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules, 2009, vol. 10, no. 5, pp. 1195–1202. doi:10.1021/bm9000298Evidence of oral translocation of anionic G6.5 dendrimers in mice / G. Thiagarajan [et al.] // Mol. Pharm. – 2013. – Vol. 10, N 3. – P. 988–998. https://doi.org/10.1021/mp300436cThiagarajan G., Sadekar S., Greish K., Ray A., Ghandehari H. Evidence of oral translocation of anionic G6.5 dendrimers in mice. Molecular Pharmaceutics, 2013, vol. 10, no. 3, pp. 988–998. doi:10.1021/mp300436cDendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model / S. Kannan [et al.] // Sci. Transl. Med. – 2012. – Vol. 4, N 130. https://doi.org/10.1126/scitranslmed.3003162Kannan S., Dai H., Navath R. S., Balakrishnan B., Jyoti A., Janisse J., Romero R., Kannan R. M. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Science Translational Medicine, 2012, vol. 4, no. 130. https://doi.org/10.1126/scitranslmed.3003162Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector / J. F. KukowskaLatallo [et al.] // Hum. Gene Ther. – 2000. – Vol. 11, N 10. – P. 1385–1395. https://doi.org/10.1089/10430340050057468Kukowska-Latallo J. F., Raczka E., Quintana A., Chen C., Rymaszewski M., Baker J. R. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Human Gene Therapy, 2000, vol. 11, no. 10, pp. 1385–1395. https://doi.org/10.1089/10430340050057468Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery / G. Navarro [et al.] // J. Control. Release. – 2010. – Vol. 146, N 1. – P. 99–105. https://doi. org/10.1016/j.jconrel.2010.04.030Navarro G., Maiwald G., Haase R., Rogach A. L., Wagner E., de Ilarduya C. T., Ogris M. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. Journal of Controlled Release, 2010, vol. 146, no. 1, pp. 99–105. https://doi.org/10.1016/j.jconrel.2010.04.030Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer / H. Maruyama-Tabata [et al.] // Gene Ther. – 2000. – Vol. 7, N 1. – P. 53–60. https://doi.org/10.1038/sj.gt.3301044Maruyama-Tabata H., Harada Y., Matsumura T., Satoh E., Cui F., Iwai M., Kita M., Hibi S., Imanishi J., Sawada T., Mazda O. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer. Gene Therapy, 2000, vol. 7, no. 1, pp. 53–60. https://doi.org/10.1038/sj.gt.3301044Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer / L. Han [et al.] // Biomaterials. – 2011. – Vol. 32, N 4. – P. 1242–1252. https://doi.org/10.1016/j.biomaterials. 2010.09.070Han L., Huang R., Li J., Liu S., Huang S., Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials, 2011, vol. 32, no. 4, pp. 1242–1252. https://doi. org/10.1016/j.biomaterials.2010.09.070Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo / L. Han [et al.] // Hum. Gene Ther. – 2010. – Vol. 21, N 4. – P. 417–426. https://doi.org/10.1089/hum.2009.087Han L., Zhang A., Wang H., Pu P., Jiang X., Kang C., Chang J. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Human Gene Therapy, 2010, vol. 21, no. 4, pp. 417–426. https://doi.org/10.1089/hum.2009.087Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2) / S. Mignani [et al] // Drug Discov. Today. ‒ 2019. ‒ Vol. 24, N 5. ‒ P. 1184–1192. https://doi.org/10.1016/j.drudis.2019.03.001.Mignani S., Rodrigues J., Roy R., Shi X., Cena V., El Kazzouli S., Majoral J.-P. Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2). Drug Discovery Today, 2019, vol. 24, pp. 1184–1192. https://doi.org/10.1016/j.drudis.2019.03.001Dendrimer toxicity: Let’s meet the challenge / K. Jain [et al] // Int. J. Pharm. ‒ 2010. ‒ Vol. 394, N 1–2. – P. 122–142. https://doi.org/10.1016/j.ijpharm.2010.04.027Jain K., Kesharwani P., Gupta U., Jain N.K. Dendrimer toxicity: Let’s meet the challenge. International Journal of Pharmaceutics, 2010, vol. 394, pp. 122–142. https://doi.org/10.1016/j.ijpharm.2010.04.027Duncan, R. Dendrimer biocompatibility and toxicity / R. Duncan, L. Izzo // Adv. Drug Deliv. Rev. ‒ 2005. ‒ Vol. 57, N 15. ‒ P. 2215–2237. https://doi.org/10.1016/j.addr.2005.09.019.Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Advanced Drug Delivery Reviews, 2005, vol. 57, pp. 2215–2237. https://doi.org/10.1016/j.addr.2005.09.019Toxicity and surface modification of dendrimers: a critical review / R. Kharwade [et al.] // Curr. Drug Deliv. ‒ 2022. – Vol. 19, N 4. ‒ P. 451–465. https://doi.org/10.2174/1567201818666211021160441Kharwade R., Badole P., Mahajan N., More S. Toxicity and surface modification of dendrimers: a critical review. Current Drug Delivery, 2022, vol. 19, pp. 451–465. https://doi.org/10.2174/1567201818666211021160441In vivo toxicity of poly(propyleneimine) dendrimers / B. Ziemba [et al.] // J. Biomed. Mater. Res. A. ‒ 2011. ‒ Vol. 99, N 2. ‒ P. 261–268. https://doi.org/10.1002/jbm.a.33196Ziemba B., Janaszewska A., Ciepluch K., Krotewicz M., Fogel W. A., Appelhans D., Voit B., Bryszewska M., Klajnert B. In vivo toxicity of poly(propyleneimine) dendrimers. Journal of Biomedical Materials Research, 2011, vol. 99, pp. 261–268. https://doi.org/ 10.1002/jbm.a.33196In vivo therapeutic applications of phosphorus dendrimers: State of the art / S. Mignani [et al.] // Drug Discov. Today. ‒ 2021. ‒ Vol. 26. ‒ P. 677‒689. https://doi.org/10.1016/j.drudis.2020.11.034Mignani S., Shi X., Ceña V., Shcharbin D., Bryszewska M., Majoral J.-P. In vivo therapeutic applications of phosphorus dendrimers: State of the art. Drug Discovery Today, 2021, vol. 26, pp. 677–689. https://doi.org/10.1016/j.drudis. 2020.11.034

The authors declare that there are no conflicts of interest present.